Stockreport

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Larimar Therapeutics, Inc.  (LRMR) 
PDF In the open label (OL) study, after 6-months of daily nomlabofusp administration, 100% of participants (n = 10) achieved skin FXN levels similar to asymptomatic carriers [Read more]